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Abstract: BACKGROUND The control of the lower urinary tract is a complex, multilevel process in-
volving both the peripheral and central nervous system. Due to lesions of the neuraxis, most spinal
cord injury patients suffer from neurogenic lower urinary tract dysfunction, which may jeopardise up-
per urinary tract function and has a negative impact on health-related quality of life. However, the
alterations to the nervous system following spinal cord injury causing neurogenic lower urinary tract
dysfunction and potential effects of treatments such as intradetrusor onabotulinumtoxinA injections on
lower urinary tract control are poorly understood. METHODS/DESIGN This is a prospective struc-
tural and functional magnetic resonance imaging study investigating the supraspinal lower urinary tract
control in healthy subjects and spinal cord injury patients undergoing intradetrusor onabotulinumtox-
inA injections for treating neurogenic detrusor overactivity.Neuroimaging data will include structural
magnetic resonance imaging (T1-weighted imaging and diffusion tensor imaging) as well as functional,
i.e. blood oxygen level-dependent sensitive magnetic resonance imaging using a 3 T magnetic resonance
scanner. The functional magnetic resonance imaging will be performed simultaneously to three differ-
ent bladder stimulation paradigms using an automated magnetic resonance compatible and synchronised
pump system.All subjects will undergo two consecutive and identical magnetic resonance imaging mea-
surements. Healthy subjects will not undergo any intervention between measurements but spinal cord
injury patients will receive intradetrusor onabotulinumtoxinA injections for treating neurogenic detrusor
overactivity.Parameters of the clinical assessment including bladder diary, urinalysis, medical history,
neuro-urological examination, urodynamic investigation as well as standardised questionnaires regarding
lower urinary tract function and quality of life will serve as co-variates in the magnetic resonance imag-
ing analysis. DISCUSSION This study will identify structural and functional alterations in supraspinal
networks of lower urinary tract control in spinal cord injury patients with neurogenic detrusor overactiv-
ity compared to healthy controls. Post-treatment magnetic resonance imaging measurements in spinal
cord injury patients will provide further insights into the mechanism of action of treatments such as
intradetrusor onabotulinumtoxinA injections and the effect on supraspinal lower urinary tract control.
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Abstract
Background: The control of the lower urinary tract is a complex, multilevel process involving both the peripheral and
central nervous system. Due to lesions of the neuraxis, most spinal cord injury patients suffer from neurogenic lower
urinary tract dysfunction, which may jeopardise upper urinary tract function and has a negative impact on
health-related quality of life. However, the alterations to the nervous system following spinal cord injury causing
neurogenic lower urinary tract dysfunction and potential effects of treatments such as intradetrusor onabotulinumtoxinA
injections on lower urinary tract control are poorly understood.
Methods/Design: This is a prospective structural and functional magnetic resonance imaging study investigating the
supraspinal lower urinary tract control in healthy subjects and spinal cord injury patients undergoing intradetrusor
onabotulinumtoxinA injections for treating neurogenic detrusor overactivity.
Neuroimaging data will include structural magnetic resonance imaging (T1-weighted imaging and diffusion tensor
imaging) as well as functional, i.e. blood oxygen level-dependent sensitive magnetic resonance imaging using a 3 T
magnetic resonance scanner. The functional magnetic resonance imaging will be performed simultaneously to three
different bladder stimulation paradigms using an automated magnetic resonance compatible and synchronised pump
system.
All subjects will undergo two consecutive and identical magnetic resonance imaging measurements. Healthy subjects will
not undergo any intervention between measurements but spinal cord injury patients will receive intradetrusor
onabotulinumtoxinA injections for treating neurogenic detrusor overactivity.
Parameters of the clinical assessment including bladder diary, urinalysis, medical history, neuro-urological examination,
urodynamic investigation as well as standardised questionnaires regarding lower urinary tract function and quality of life
will serve as co-variates in the magnetic resonance imaging analysis.
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Discussion: This study will identify structural and functional alterations in supraspinal networks of lower urinary tract
control in spinal cord injury patients with neurogenic detrusor overactivity compared to healthy controls. Post-treatment
magnetic resonance imaging measurements in spinal cord injury patients will provide further insights into the mechanism
of action of treatments such as intradetrusor onabotulinumtoxinA injections and the effect on supraspinal lower urinary
tract control.
Trial registration: ClinicalTrials.gov NCT01768910.
Keywords: Urinary bladder, Spinal cord injury, Neuroimaging, Magnetic resonance imaging, Neurogenic detrusor
overactivity, OnabotulinumtoxinA intradetrusor injections
Background
Spinal cord injury (SCI) is a devastating event with far-
reaching consequences for the individual’s health and the
economic and social future. In the past, renal failure due to
neurogenic lower urinary tract dysfunction (NLUTD) was a
leading cause of death after SCI [1]. Furthermore, NLUTD
has a highly negative impact on patients’ quality of life
(QoL). Acute SCI initially causes “spinal shock”, charac-
terised by an acontractile/hypocontractile detrusor and
urinary retention, which in case of a suprasacral lesion
(today the vast majority of SCI) is followed by development
of detrusor overactivity mostly combined with detrusor
sphincter dyssynergia [2]. Antimuscarinics are the pharma-
cological first-line treatment for detrusor overactivity al-
though the effectiveness is limited [3]. In addition, many
patients discontinue antimuscarinics due to bothersome
side-effects [4]. Thus, intradetrusor onabotulinumtoxinA
injections have become an established, highly effective,
minimally invasive, and generally well-tolerated therapy for
refractory detrusor overactivity [5] to improve patients’
health and QoL [6]. Despite the popularity of intradetrusor
onabotulinumtoxinA injections, the exact mechanisms of
action remain to be elucidated. Nevertheless, it seems
highly probable that, in addition to a direct efferent effect
by blocking the presynaptic release of acetylcholine from
the parasympathetic innervation resulting in temporary
chemodenervation of the detrusor, onabotulinumtoxinA
also modulates afferent pathways [7]. It is, however, not
known whether this treatment can normalise alterations in
supraspinal areas and whether supraspinal modulation cor-
relates with clinical improvements.
The control of the lower urinary tract (LUT) is a
complex, multilevel process that involves both the
peripheral and central nervous system but the exact
mechanisms involved in humans are still incompletely
understood [8]. Neuroimaging studies over the last dec-
ade have consistently pointed to a complex supraspinal
network that controls LUT function [9]. These studies
tremendously increased our understanding of how hu-
man LUT function is coordinated and how it can be af-
fected by neurological disorders. Recent neuroimaging
studies demonstrated reorganisation of supraspinal ac-
tivity in response to LUT stimulation tasks in patients
with disorders such as Parkinson’s disease [10-12] and
SCI [13] as compared to healthy controls, which might
represent the neural correlate of their NLUTD.
Cortical and sub-cortical (for example, brainstem)
brain regions are essential for voluntary LUT control
[9,14,15]. Investigation of the supraspinal regions with
high-resolution imaging techniques, for example, struc-
tural magnetic resonance imaging (MRI) and functional
MRI (fMRI), can significantly increase our knowledge
on the effects of supraspinal lesions and alterations
related to NLUTD [9,16]. Although diffusion tensor
imaging (DTI) [17] is popular in other fields in neuro-
science, it has only been applied in the context of
supraspinal LUT control in one prospective study [18]
in patients with non-neurogenic LUT symptoms.
In this study, we will first identify supraspinal areas
associated with LUT control in SCI patients with neuro-
genic detrusor overactivity and healthy controls. Subse-
quently, we will investigate the effects of intradetrusor
onabotulinumtoxinA injections on supraspinal areas.
Task-related blood oxygen level-dependent (BOLD)
fMRI will be used along structural MRI (T1-weighted
and DTI). Moreover, we will examine volumetric
parameters (for example, grey and white matter concen-
tration) by voxel- (VBM) [19] and tensor-based morph-
ometry (TBM) [20], structural integrity and connectivity
of white matter tracts (DTI) as well as structural (SC)
and functional connectivity (FC).
This unique and detailed multimodal imaging and
clinical approach will distinguish the different structural
and functional processing units involved during suprasp-
inal LUT control and will identify dysfunctional neuronal
components in SCI patients responsible for neurogenic
detrusor overactivity.
For a test-retest validation, we will additionally investi-
gate the reliability [21] of BOLD signals in task-related
fMRI in healthy controls by the intra-class correlation
coefficient (ICC) for absolute or consistent agreement of
participants activations over two visits.
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Methods/Design
Study design
This prospective research study will be conducted at the
University of Zürich, Zürich, Switzerland in cooperation
with our partner, the institute of Neuro-Radiology,
University of Zürich, University Hospital Zürich, Zürich,
Switzerland.
Study location
The study has two study locations, that is, the department
of Neuro-Urology, Spinal Cord Injury Centre & Research,
University of Zürich, Balgrist University Hospital, Zürich,
Switzerland (first and third visit, see below) and the MR-
Centre, University Hospital Zürich, Zürich, Switzerland
(second and third visit, see below).
Study population and recruitment
In line with the inclusion and exclusion criteria
(Table 1), we will investigate SCI patients with
neurogenic detrusor overactivity and healthy controls
with an unimpaired LUT function. Participants of
both groups will be similar according to age and
gender.
20–24 SCI patients with neurogenic detrusor over-
activity refractory to antimuscarinics and scheduled
for study independent intradetrusor onabotulinum-
toxinA injections and 12–24 healthy controls will be
recruited.
Interventions
Subjects providing written informed consent will be in-
vited for the following visits (Figure 1):
Screening (Visit 1): Evaluation for study eligibility will
be based on medical history, urinalysis to exclude urinary
tract infection (UTI) and pregnancy in female participants,
3-day bladder diary, post void residual, urodynamic
parameters as well as on standardised validated question-
naires such as Qualiveen [22] and International Consult-
ation on Incontinence modular questionnaire [(ICIQ),
Bristol Urological Institute, Southmead Hospital Bristol,
UK] assessing lower urinary tract symptoms (LUTS) in
both woman (ICIQ-FLUTS) and men (ICIQ-MLUTS).
MRI measurements (Visit 2 and 3, Figure 1): Two
MRI measurements will be performed in identically
manner within a 5 to 7 weeks interval.
Both MRI measurements will be performed using a Phi-
lips Ingenia 3 Tesla MR scanner (Philips Medical Systems,
Best, The Netherlands) with a 16-channel head coil to ac-
quire the following sequences (Figure 2):
 Structural sequences will comprise T1-weighted and
DTI.
 Functional sequences will comprise three different
task-related fMRI paradigms (Figure 3).
 In the first two task-related fMRI paradigms, we
will examine the effect of visceral bladder sensa-
tion by automated, repetitive bladder filling with
100 mL body warm (37°C) saline starting with an
Table 1 Inclusion and exclusion criteria for all participants
Groups Inclusion criteria Exclusion criteria
All participants • MR suitability • Pregnancy or breast feeding
• Written informed consent • Any anatomical anomaly of LUT/genitalia
• Any LUT malignancy
• Claustrophobia
SCI patients • Age limit: > 18 years • Symptomatic UTI
• Neurogenic detrusor overactivity
• Refractory to antimuscarinic treatment
• Scheduled for intradetrusor onabotulinumtoxinA injections
Healthy controls • Age limits: > 18 years • Impaired LUT function
• Unimpaired LUT function • Any LUTS (3-day bladder diary)
• No LUTS (3-day bladder diary) • Any number of episodes of urinary urgency/week
• No episode of urinary urgency/week • Urinary frequency > 8/24 h
• Urinary frequency < 8/24 h • Any craniocerebral injury or surgery
• Any permanent ferromagnetic implant
• Any previous surgery of LUT/genitalia
• UTI
• PVR > 150 mL
LUT = lower urinary tract, LUTS = lower urinary tract symptoms, MR =magnetic resonance, PVR = post void residual, SCI = spinal cord injury, UTI = urinary
tract infection.
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empty bladder (first paradigm) and a bladder
volume eliciting desire to void (second
paradigm).
 The third task-related fMRI paradigm will
contain automated, repetitive filling of 100 mL
cold (4-8°C) saline starting with an empty
bladder.
Repetitive filling will be performed using an automated
MR-compatible and MR-synchronised pump system [18]
to precisely fill and drain the bladder. During the MRI
measurements, all participants will use an MR-compatible
handheld response system [23] to rate their desire to void
and level of pain on a displayed visual analogue scale.
Study outcome measures
Primary
(A)Task-related BOLD signal intensity in supraspinal
regions of interest (ROI) in SCI patients with
neurogenic detrusor overactivity compared to healthy
controls.
(B) Supraspinal morphometry of ROIs in SCI patients
with neurogenic detrusor overactivity compared to
healthy controls.
(C) SC and FC between ROIs of the supraspinal LUT
controlling circuitries in SCI patients with
neurogenic detrusor overactivity and healthy
controls.
(D)Changes of task-related BOLD signal intensity, SC and
FC between ROIs in SCI patients with neurogenic de-
trusor overactivity before and after study independent
intradetrusor onabotulinumtoxinA injections.
Secondary
(A)Reliability of BOLD signal changes between first
and second MRI measurement in healthy controls.
(B) Correlations between clinical co-variates that are
bladder diary parameters, urodynamic parameters,
level of desire to void during fMRI and task-related
Figure 1 Timetable and characteristics of all visits. *Patients only, Treatment = intradetrusor onabotulinumtoxinA injection, MRI =magnetic
resonance imaging, PVR = post void residual
Figure 2 Sequences of magnetic resonance imaging (MRI)
measurements. *Bladder will be filled with body warm saline until
a persistent desire to void is present.
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BOLD signal intensity in supraspinal ROIs as well
as structural parameters, that is, grey matter
volume and number of white matter tracts between
ROIs.
Data analysis
Clinical data, for example, questionnaires scores, urody-
namic parameters and 3-day bladder diary outcomes
will be statistically analysed and compared between
groups using IBM’s Statistical Package for the Social Sci-
ences (SPSS) version 19.0 or newer (Armonk, New
York, U.S.). The statistical analysis will be presented
with means and standard deviations or with medians
and interquartile ranges as appropriate.
For the analysis of the neuroimaging data, we will use
statistical parametric mapping (SPM) V.8 or newer (Well-
come Department of Imaging Neuroscience, University
College London, UK) and toolboxes as appropriate.
Regulatory issues
Ethical approval
This study has been approved by the local ethics com-
mittee (Kantonale Ethikkommission Zürich, KEK-ZH-
Nr. 2011–0346) and will be performed in accordance to
the World Medical Association Declaration of Helsinki
[24], the guidelines for Good Clinical Practice (GCP)
[25], and the guidelines of the Swiss Academy of Med-
ical Sciences [26]. Handling of all personal data will
Figure 3 Scan paradigm of three different task-related functional MRIs (fMRIs). All task-related fMRIs identically start with a ‘baseline’ rest
(60 s, no specific stimulus or task is performed), a ‘baseline’ rating (desire to void and level of pain), a short rest (jittered between 7 and 9 s in
which blood oxygen level-dependent (BOLD) activation resulting from motor activity during the previous rating will return to baseline to avoid
contamination of the following condition) and conclude with a ‘last’ rest (60 s, no specific stimulus or task is performed). All task-related fMRIs
consist of eight repetitive blocks, each with either five (first and third fMRIs) or eight (second fMRI) conditions. (A) Conditions of the first task-
related fMRIs: (1) automated infusion of 100 mL body warm saline, (2) plateau phase (bladder distention after infusion is perceived), (3) rating, (4)
passive withdrawal to empty the bladder completely and (5) short rest. This task-related fMRI starts with an empty bladder. (B) Conditions of the
second task-related fMRIs: (1) automated infusion of 100 mL warm saline, (2) plateau phase, (3) rating, (4) short rest, (5) automated withdrawal of
100 mL, (6) plateau phase (bladder distention after withdrawal is perceived), (7) rating and (8) short rest. *This task-related fMRI (B) starts with a
high prefilled bladder volume, that is, the bladder will be filled with body warm saline until a persistent desire to void is present. (C) Conditions
of the third task-related fMRIs: (1) automated infusion of 100 mL cold (4–8°C) saline, (2) plateau phase, (3) rating, (4) passive withdrawal to empty
the bladder completely and (5) short rest. This task-related fMRI starts with an empty bladder.
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strictly comply with the federal law of data protection in
Switzerland [27].
Safety
According to the safety regulations of the MR-Centre of
the University Hospital Zürich, the staff involved in this
study will be instructed and trained. Prior to entering the
scanner room, all participants will be asked to remove any
ferromagnetic items (for example, bra, chains, earrings,
rings, and piercings). All participants will be provided with
standardised clinical scrubs to prevent incidental import of
ferromagnetic items into the MR room. To exclude UTI or
pregnancy, urinalysis will be performed on every participant
before urodynamic investigations and MR measurements.
In case of pregnancy, the participant will be excluded from
the study and referred to a gynaecologist. In case of UTI,
the participant will not undergo the experiment but will
be treated appropriately. After successful treatment, a re-
assignment to the study is possible.
In case of an adverse event (AE) or a severe adverse event
(SAE), as defined by the International Organization for
Standardization (ISO, 14155) [28] and the International
Conference on Harmonisation (ICH) GCP guidelines (E6)
[25], responsible authorities, that is, the principle investiga-
tor and the ethics committee will be informed. Appropriate
actions will be executed. All AEs and SAEs will be followed
as long as medically indicated.
Funding
The Swiss National Science Foundation (grant number:
135774), Wings for Life, the Emily Dorothy Lagemann
Stiftung and the Swiss Continence Foundation are fund-
ing this study.
Discussion
This study will investigate structural and functional abnor-
malities and specific alterations in the brain networks of
supraspinal LUT control in SCI patients with neurogenic
detrusor overactivity compared to healthy controls using a
multimodal imaging protocol. Importantly, effects on the
supraspinal LUT control after treatment for neurogenic
detrusor overactivity with intradetrusor onabotulinumtox-
inA injections in SCI patients will be explored.
The findings will help to verify, amend, or adjust neur-
onal circuitry models established from findings in healthy
controls, now in the context of SCI patients with neuro-
genic detrusor overactivity. Furthermore it will show
whether neurogenic detrusor overactivity specific treat-
ment such as intradetrusor onabotulinumtoxinA injec-
tions induce structural or functional reorganisation in
supraspinal areas related to LUT control and in how far
such changes correlate with improvements of clinical out-
come parameters. These investigations will help us to
understand how onabotulinumtoxinA modulates afferent
pathways.
Advanced neuroimaging and evaluation techniques have
the potential to serve as quantifiable outcome measures
for therapy success and for improving our treatment strat-
egies in this patient population.
Trial status
The trial is in the recruiting phase at the time of manu-
script submission.
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